Combination therapy of anti-CTLA-4 and anti-PD-1 antibodies is effective in mouse models [87] and in patients with melanoma [88], renal cell carcinoma (RCC) [89], and lung cancer [90]. This evidence concerns the gene PDCD1 and renal cell carcinoma.